Jay Luly

(Dr. Jay Luly Ph.D.)

Currently holds a position at Enanta Pharmaceuticals Inc

Positions

Position Company Period
President, Chief Executive Officer, Director Enanta Pharmaceuticals Inc July 1, 2003 -
Jay Luly's trades of Enanta Pharmaceuticals Inc's stock


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PS: Planned sale, O: Option / Other
Notification date Transaction date B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2025-02-12 2025-02-12
B Purchase
45,000 +5.6%
5.69
USD 256,050 		45,000 +5.6% 5.69 USD 256,050
2024-12-10 2024-12-06
S Sale
5,142 -0.6%
8.06
USD 41,445 		5,142 -0.6% 8.06 USD 41,445
2023-12-06 2023-12-05
S Sale
7,230 -0.9%
9.63
USD 69,625 		7,230 -0.9% 9.63 USD 69,625
2023-03-14 2023-03-13
PS Planned sale
1,566 -0.2%
46.13
USD 72,240 		1,566 -0.2% 46.13 USD 72,240
2023-03-14 2023-03-13
PS Planned sale
15,649 -1.9%
45.31
USD 709,056 		15,649 -1.9% 45.31 USD 709,056
2023-03-14 2023-03-13
PS Planned sale
10,697 -1.3%
44.81
USD 479,333 		10,697 -1.3% 44.81 USD 479,333
2022-12-16 2022-12-16
PS Planned sale
13,603 -1.7%
45.49
USD 618,800 		13,603 -1.7% 45.49 USD 618,800
2022-12-16 2022-12-16
PS Planned sale
8,597 -1.1%
44.54
USD 382,910 		8,597 -1.1% 44.54 USD 382,910
2022-12-16 2022-12-16
PS Planned sale
7,800 -1.0%
43.59
USD 340,002 		7,800 -1.0% 43.59 USD 340,002
2021-09-17 2021-09-15
PS Planned sale
4,516 -0.7%
59.06
USD 266,698 		4,516 -0.7% 59.06 USD 266,698
// ... existing code ... // ... rest of the file ...